Author Correction: Targeted therapy in patients with PIK3CA-related overgrowth syndrome (Nature, (2018), 558, 7711, (540-546), 10.1038/s41586-018-0217-9);Targeted therapy in patients with PIK3CA-related overgrowth syndrome

Nature

Volumn 558, Issue 7711, 2018, Pages 540-546

  Venot, Quitterie ^a   Blanc, Thomas ^a,b,c   Rabia, Smail Hadj ^b,c   Berteloot, Laureline ^c   Ladraa, Sophia ^a   Duong, Jean Paul ^b,c   Blanc, Estelle ^d   Johnson, Simon C ^e   Hoguin, Clément ^a   Boccara, Olivia ^c   Sarnacki, Sabine ^b,c   Boddaert, Nathalie ^b,c   Pannier, Stephanie ^b,c   Martinez, Frank ^c   Magassa, Sato ^a   Yamaguchi, Junna ^a   Knebelmann, Bertrand ^a,b,c   Merville, Pierre ^f,g   Grenier, Nicolas ^f   Joly, Dominique ^a,b,c   Cormier Daire, Valérie ^b,c   Michot, Caroline ^b,c   Bole Feysot, Christine ^c   Picard, Arnaud ^b,c   Soupre, Véronique ^c   Lyonnet, Stanislas ^b,c   Sadoine, Jeremy ^h   Slimani, Lotfi ^h   Chaussain, Catherine ^b,h   Laroche Raynaud, Cécile ⁱ   Guibaud, Laurent ^j   Broissand, Christine ^c   Amiel, Jeanne ^b,c   Legendre, Christophe ^a,b,c   Terzi, Fabiola ^a,b   Canaud, Guillaume ^a,b,c   more..

^a INSTITUT NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^e SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^f HÔPITAL PELLEGRIN   (France)

^g CNRS   (France)

^h and Plateforme d'Imagerie du Vivant   (France)

ⁱ Hôpital de la Mère et de l'Enfant   (France)

^j HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPELISIB; PLACEBO; PROTEIN KINASE B; RAPAMYCIN; NVP-BYL719; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

COGNITION; DISEASE TREATMENT; GENE; GENETIC ANALYSIS; INHIBITION; INHIBITOR; NERVOUS SYSTEM DISORDER; SURVIVAL; SYMPTOM;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHILD; CLINICAL ARTICLE; CLOVES SYNDROME; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIBROBLAST; GENETIC DISORDER; HEMIHYPERTROPHY; HUMAN; HUMAN TISSUE; MALE; MOLECULARLY TARGETED THERAPY; MORNING DOSAGE; MOUSE; NONHUMAN; PIK3CA RELATED OVERGROWTH SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; SCOLIOSIS; VASCULAR TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; CASE REPORT; CLINICAL TRIAL; COMPLICATION; CONGENITAL BLOOD VESSEL MALFORMATION; DISEASE MODEL; ENZYMOLOGY; HEART FAILURE; HELA CELL LINE; LIPOMA; METABOLISM; MUSCULOSKELETAL SYSTEM MALFORMATION; NEVUS; PHENOTYPE; SYNDROME;

ADULT; ANIMALS; CHILD; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; DISEASE MODELS, ANIMAL; FEMALE; HEART FAILURE; HELA CELLS; HUMANS; LIPOMA; MALE; MICE; MOLECULAR TARGETED THERAPY; MUSCULOSKELETAL ABNORMALITIES; NEVUS; PHENOTYPE; SCOLIOSIS; SIROLIMUS; SYNDROME; THIAZOLES; VASCULAR MALFORMATIONS; VASCULAR NEOPLASMS;

EID: 85049116902     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-019-1109-3     Document Type: Erratum

References (27)

1. Vanhaesebroeck, B., Stephens, L. & Hawkins, P. PI3K signalling: The path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13, 195-203 (2012).
2. Hiles, I. D. et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell 70, 419-429 (1992).
3. Stephens, L. et al. Protein kinase B kinases that mediate phosphatidylinositol 3, 4, 5-trisphosphate-dependent activation of protein kinase B. Science 279, 710-714 (1998).
4. Manning, B. D. & Toker, A. AKT/PKB signaling: navigating the network. Cell 169, 381-405 (2017).
5. Keppler-Noreuil, K. M. et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am. J. Med. Genet. A. 167A, 287-295 (2015).
6. Keppler-Noreuil, K. M. et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am. J. Med. Genet. A. 164A, 1713-1733 (2014).
7. Kurek, K. C. et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am. J. Hum. Genet. 90, 1108-1115 (2012).
8. Canaud, G. et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat. Med. 19, 1288-1296 (2013).
9. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562 (2009).
10. Furet, P. et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg. Med. Chem. Lett. 23, 3741-3748 (2013).
11. Fritsch, C. et al. Characterization of the novel and specific PI3K inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther. 13, 1117-1129 (2014).
12. Mayer, I. A. et al. A phase Ib study of alpelisib (BYL719), a PI3K-specific inhibitor, with letrozole in ER+/HER2 metastatic breast cancer. Clin. Cancer Res. 23, 26-34 (2017).
13. Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573-586 (2009).
14. Klippel, A. et al. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol. Cell. Biol. 16, 4117-4127 (1996).
15. Hayashi, S. & McMahon, A. P. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: A tool for temporally regulated gene activation/inactivation in the mouse. Dev. Biol. 244, 305-318 (2002).
16. Castillo, S. D. et al. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans. Sci. Transl. Med. 8, 332ra43 (2016).
17. Hare, L. M. et al. Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects. Dev. Biol. 404, 14-26 (2015).
18. Mirzaa, G. et al. PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. JCI Insight 1, e87623 (2016).
19. Kinross, K. M. et al. Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly. FASEB J. 29, 1426-1434 (2015).
20. Hammill, A. M. et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr. Blood Cancer 57, 1018-1024 (2011).
21. O'Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
22. Heitman, J., Movva, N. R. & Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905-909 (1991).
23. Velarde-Jurado, E. & Avila-Figueroa, C. [Evaluation of the quality of life]. Salud Publica Mex. 44, 349-361 (2002).
24. Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649-655 (1982).
25. Seluanov, A., Vaidya, A. & Gorbunova, V. Establishing primary adult fibroblast cultures from rodents. J. Vis. Exp. 2010, 2033 (2010).
26. Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034 (2002).
27. Canaud, G. et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N. Engl. J. Med. 371, 303-312 (2014).